The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells
Open accessAbstract
Glucose-dependent insulinotropic polypeptide (GIP) acts as a glucose-dependent growth factor for beta-cells. Here we show that GIP and glucose also act synergistically as anti-apoptotic factors for beta-cells, using the well-differentiated beta-cell line, INS-1. Mitogenic and anti-apoptotic signaling of GIP were dependent upon pleiotropic activation of protein kinase A (PKA)/cAMP regulatory element binder (CREB), mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3-kinase)/PKB signaling modules. The signaling modules activated by GIP were dependent on glucose metabolism and calcium influx and were tightly linked by multiple activating and inhibiting cross-talk. These interactions included: (i) a central role of tyrosine phosphorylation for stimulation of PKA/CREB, MAPK and PI3-kinase/PKB, (ii) inhibition of PKA/CREB by the MAPK pathway at the level of MAPK kinase-1 or downstream, (iii) activation of MAPK signaling by PI3-kinase and PKA at the level of extracellular-signal regulated kinase 1/2 or upstream, and (iv) activation of PKB by MAPK and PKA signaling at the level of PKB or upstream. Furthermore, we demonstrated inhibition of CREB signaling by Ca(2+)/calmodulin kinase I/IV. These results indicated that GIP acts as a mitogenic and anti-apoptotic factor for beta-cells by pleiotropic activation of tightly linked signaling pathways in beta-cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454 · cited 1×
“A knockout of the GIP receptor demonstrated not only a defect in the entero–insular axis, but also a diminished metabolic adaptation of -cells under conditions of insulin resistance induced by a high-fat diet (Miyawaki et al. 1999).”
BackgroundGIF biology and fat metabolism
Yip, R. G. C., & Wolfe, M. M. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00314-8 · Cited by 266
Volz, A., Göke, R., Lankat-Buttgereit, B., Fehmann, H.-C., Bode, H. P., & Göke, B. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)01006-z · Cited by 96
Cited by
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Pancreatic regulation of glucose homeostasis.
Röder, P. V., Wu, B., Liu, Y., & Han, W. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.6 · Cited by 985
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“Similar to GLP-1-induced -cell prolif- eration, antiapoptotic effects of GLP-1 in cells are mediated by promotion of FoxO1 nuclear exclusion and consequent up-regulation of PDX-1 and Foxa2 expression via EGFR- and PI-3K-dependent activation of PKB and cAMP/PKA-dependent activation of CREB, leading to up-regulation of…”
BackgroundInfluentialGIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746
The role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 614
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Brubaker, P. L., & Drucker, D. J. (2004) · Endocrinology · doi:10.1210/en.2004-0015 · Cited by 540
Glucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis
Drucker, D. J. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0306 · Cited by 483
Mu, J., Woods, J., Zhou, Y.-P., Roy, R. S., Li, Z., Zycband, E., Feng, Y., Zhu, L., Li, C., Howard, A. D., et al. (2006) · Diabetes · doi:10.2337/db05-1602 · Cited by 449
Parker, H. E., Habib, A. M., Rogers, G. J., Gribble, F. M., & Reimann, F. (2009) · Diabetologia · doi:10.1007/s00125-008-1202-x · Cited by 324
“Nevertheless, GIP, like GLP-1, has beneficial proliferative and anti-apoptotic effects on pancreatic islet cells [9], and dipeptidyl peptidase IV-resistant GIP analogues have been shown to improve glucose homeostasis in normal, obese and diabetic rodents [10, 11].”
Glucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288
“Recently, an introduction of cell growth as well as an inhibition of apoptosis were described during GIP administration in INS-1 cells [237,238].”
BackgroundMechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
Hurley, R. L., Barré, L. K., Wood, S. D., Anderson, K. A., Kemp, B. E., Means, A. R., & Witters, L. A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606676200 · Cited by 263
Song, D. H., Getty–Kaushik, L., Tseng, E., Simon, J., Corkey, B. E., & Wolfe, M. M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.09.005 · Cited by 137
Growth factors and beta cell replication
Vasavada, R. C., Gonzalez-Pertusa, J. A., Fujinaka, Y., Fiaschi-Taesch, N., Cozar-Castellano, I., & Garcia-Ocaña, A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.08.003 · Cited by 133
Pamir, N., Lynn, F. C., Buchan, A. M. J., Ehses, J., Hinke, S. A., Pospisilik, J. A., Miyawaki, K., Yamada, Y., Seino, Y., McIntosh, C. H. S., et al. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00270.2002 · Cited by 126
“In this regard, our finding of increased -cell area in GIPR/ mice is not fully understood (10, 38 , 39).”
BackgroundGreen, B., Gault, V., O'Harte, F., & Flatt, P. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043382774 · Cited by 111
Portha, B., Tourrel-Cuzin, C., & Movassat, J. (2011) · Experimental Diabetes Research · doi:10.1155/2011/376509 · Cited by 85
Mart�n, J., Usac, E. F., Franco, C., Barbacid, M., Gomis, R., Marzo, N., Mora, C., & Fabregat, M. E. (2004) · Diabetologia · doi:10.1007/s00125-004-1372-0 · Cited by 65
Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist
Tall Bull, S., Nuffer, W., & Trujillo, J. M. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108332 · Cited by 43
The GIP/GIPR axis in medullary thyroid cancer: clinical and molecular findings
Regazzo, D., Bertazza, L., Galletta, E., Barollo, S., Mondin, A., Zovato, S., Iacobone, M., Zilio, E., Scaroni, C., Radu, C. M., et al. (2022) · Endocrine-Related Cancer · doi:10.1530/erc-21-0258 · Cited by 17
Metadata
- Authors
- Trumper, A., Trumper, K., & Horsch, D.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2002-08-01
- Volume
- 174
- Issue
- 2
- Pages
- 233-246
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2089109393
- Cited by
- 193
- References
- 3
- FWCI
- 9.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.